Concepedia

Author

Dayu Shi

Peking University People's HospitalORCID

Also Known As

D Shi, D Y Shi, Da-Yu Shi, Dayu Shi, Decai Shi, Dong-Cheng Shi, Dongyu Shi

24

Publications

241

Citations

9

H-Index

8

Concepts

All Affiliations

Peking University People's HospitalPeking UniversitySoochow UniversitySun Yat-sen UniversitySun Yat-sen University Cancer Center
DS

About

Dayu Shi is an author at Peking University People's Hospital specializing in psychiatry, mental health, and depression.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

18

2

Social Sciences

1

1

18

3

Psychiatry

1

1

18

4

Psychology

1

1

18

5

Mental Health

1

1

18

Dayu Shi

×

7

Publications

141

Citations

7

H-Index

YearCitations

Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation

Jing-Rui Zhou, Dayu Shi, Rong Wei,

Frontiers in Immunology

2021

37

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Qian Jiang, Xiao‐Jun Huang, Zi Chen,

Blood

2019

27

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, Xiao‐Jun Huang, Zi Chen,

Blood

2020

25

Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Dayu Shi, Zongru Li, Yongjie Li,

Leukemia & lymphoma/Leukemia and lymphoma

2020

18

Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)

Qian Jiang, Dayu Shi, Zongru Li,

Blood

2021

12

Phlegmonous gastritis in a patient with mixed-phenotype acute leukemia in the neutropenia phase during chemotherapy

Dayu Shi, Jin-de He, Meng Lv,

Medicine

2019

11

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant <i>BCR-ABL1 T315I</i>-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Qian Jiang, Dayu Shi, Zongru Li,

Blood

2021

11

Page 1